(NASDAQ:RPRX) NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):
Related Questions
What are the coupon rate, maturity, and any covenants attached to the $2.0 billion senior unsecured notes, and how will they affect Royalty Pharma's cost of capital?
How does Royalty Pharma intend to use the proceeds from the note issuance, and what impact could that have on its cash flow, debt profile, and growth initiatives?
How does this financing compare to recent debt offerings by peer companies in the pharma royalty space, and what implications does it have for the company's credit rating and stock valuation?